Goldman Sachs Reiterates Buy Rating on Braveheart Bio Shares

Goldman Sachs has reaffirmed its buy rating for Braveheart Bio shares on NASDAQ. Analyst Salveen Richter maintains the recommendation, alongside a price target of $48.00 per share.

This represents an approximately 80% upside from the current market price of $26.64.

Braveheart Bio is a biotechnology company with a market capitalization of over $1.7 billion.

The firm's focus on BHB-1893, a cardiac myosin inhibitor, has garnered significant attention and support from various analyst firms.